All Biopharmaceuticals articles
-
-
Journal
Innovating and harmonising access and requirements amid the global regulatory challenges of biologics
This article provides an overview of the regulatory challenges of biologics facing the biopharmaceutical industry, focusing on the need for global regulatory harmonisation. These challenges are central to ensuring the safety, efficacy and accessibility of biologic therapies for patients worldwide. To navigate these regulatory challenges, a collaborative effort will be ...
-
Journal
Quality management systems — applying good distribution practices to the biopharmaceutical supply chain
Biopharmaceutical supply chain strategies and alignment with good distribution practices (GDPs) are often viewed and planned with a focus on the post-marketing stage. Although this approach is valid, GDP compliance and supply chain strategies have important implications even during the clinical phases of product development. GDP regulations ensure that the integrity of medicinal products is maintained throughout all stages of the supply chain, from the manufacturer’s site to the pharmacy, or person authorised to supply to the public.
-
Journal
Regulatory complexities and challenges of biosimilars
This continuing professional development (CPD) supplement focuses on the regulatory complexities and challenges associated with biosimilar products and their development. Although biosimilar products have been registered and approved for use in the EU for more than a decade, there is increasing speculation and excitement on the potential for biosimilars with increasingly complex structures, eg, multi-subunit, extensively post-translationally modified, and lipid-containing products.
-
Journal
Nonclinical immunogenicity evaluation in toxicology studies of biopharmaceuticals
One of the critical features that determines the clinical efficacy and safety of biotherapeutics, especially therapeutic proteins, is their ability to induce formation of antibodies against themselves. However, the clinical outcome cannot be predicted using the immunogenicity data from nonclinical studies…